Towards personalized therapy for multiple sclerosis: prediction of individual treatment response
暂无分享,去创建一个
Pierre Grammond | Patrizia Sola | Murat Terzi | Fraser Moore | Jan Hillert | Guillermo Izquierdo | Helmut Butzkueven | Maria Trojano | Freek Verheul | Ali Manouchehrinia | Dana Horakova | Alessandra Lugaresi | Tim Spelman | Lukas Sobisek | Francois Grand'Maison | Suzanne Hodgkinson | Steve Vucic | Pamela McCombe | Michael Barnett | Raed Alroughani | Tomas Kalincik | Franco Granella | Roberto Bergamaschi | Cavit Boz | Gerardo Iuliano | Daniele Spitaleri | Vahid Shaygannejad | J. Lechner-Scott | M. Slee | M. Trojano | F. Grand'Maison | V. Shaygannejad | E. Havrdová | H. Butzkueven | R. Bergamaschi | M. Barnett | G. Izquierdo | M. Amato | A. Lugaresi | C. Boz | J. Hillert | S. Vucic | C. Oreja-Guevara | P. Mccombe | P. Duquette | P. Sola | F. Granella | E. Cristiano | R. Hupperts | A. Prat | M. Girard | T. Spelman | D. Horáková | T. Kalincik | P. Grammond | V. van Pesch | G. Iuliano | F. Verheul | F. Moore | M. Saladino | R. Alroughani | V. Jokubaitis | E. Pucci | S. Hodgkinson | Maria Pia Amato | Marc Girard | Pierre Duquette | Alexandre Prat | L. Sobíšek | A. Manouchehrinia | C. Rózsa | Eva Havrdova | M. Terzi | D. Spitaleri | C. Ramo-Tello | J. Olascoaga | R. Ampapa | J. Sanchez-Menoyo | S. Flechter | Raymond Hupperts | Mark Slee | Vilija Jokubaitis | Eugenio Pucci | Vincent Van Pesch | Radek Ampapa | Edgardo Cristiano | Javier Olascoaga | Maria Laura Saladino | Csilla Rozsa | Shlomo Flechter | Jeannette Lechner‐Scott | Celia Oreja‐Guevara | Cristina Ramo‐Tello | Jose Luis Sanchez‐Menoyo | C. Rozsa | J. Sánchez-Menoyo
[1] G. Coppola,et al. Long‐term clinical experience with weekly interferon beta‐1a in relapsing multiple sclerosis , 2006, European journal of neurology.
[2] Clinical characteristics of responders to interferon therapy for relapsing MS , 2003, Neurology.
[3] J. Sargento-Freitas,et al. Clinical predictors of an optimal response to natalizumab in multiple sclerosis , 2013, Journal of Clinical Neuroscience.
[4] N. Koch-Henriksen,et al. Prediction of response to interferon therapy in multiple sclerosis , 2014, Acta neurologica Scandinavica.
[5] G. Izquierdo,et al. Immunological markers of optimal response to natalizumab in multiple sclerosis. , 2012, Archives of neurology.
[6] C. Pozzilli,et al. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis , 2012, Journal of the Neurological Sciences.
[7] J. Kurtzke. Rating neurologic impairment in multiple sclerosis , 1983, Neurology.
[8] E. Havrdová,et al. Early predictors of non‐response to interferon in multiple sclerosis , 2012, Acta neurologica Scandinavica.
[9] S. Sorbi,et al. Response to interferon-beta therapy in relapsing-remitting multiple sclerosis: a comparison of different clinical criteria , 2006, Multiple sclerosis.
[10] F. Mcdowell,et al. PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS , 1965, Annals of the New York Academy of Sciences.
[11] M. Trojano,et al. Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy , 2003, Multiple sclerosis.
[12] Pierre Grammond,et al. Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis , 2016, Journal of Neurology, Neurosurgery & Psychiatry.
[13] S. Reingold,et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.
[14] S. Mahurkar,et al. Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature. , 2014, Autoimmunity reviews.
[15] L. Blumhardt,et al. Benefits of glatiramer acetate on disability in relapsing–remitting multiple sclerosis An analysis by area under disability/time curves , 2000, Journal of the Neurological Sciences.
[16] J. Leeuw,et al. Simple and Canonical Correspondence Analysis Using the R Package anacor , 2007 .
[17] F. Jacques. Defining the clinical course of multiple sclerosis: The 2013 revisions , 2015, Neurology.
[18] X. Montalban,et al. Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonβ therapy in multiple sclerosis , 2011, Genes and Immunity.
[19] Pierre Grammond,et al. Defining secondary progressive multiple sclerosis. , 2016, Brain : a journal of neurology.
[20] Pierre Grammond,et al. Defining reliable disability outcomes in multiple sclerosis. , 2015, Brain : a journal of neurology.
[21] J. Lechner-Scott,et al. Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis , 2016, European journal of neurology.
[22] Wayne Nelson. Theory and Applications of Hazard Plotting for Censored Failure Data , 2000, Technometrics.
[23] H. Falah,et al. Secondary Progressive Multiple Sclerosis: What is in the , 2014 .
[24] S. Martínez-Yélamos,et al. Baseline MxA mRNA Expression Predicts Interferon Beta Response in Multiple Sclerosis Patients , 2014, PloS one.
[25] J. Hillert,et al. The Swedish MS registry – clinical support tool and scientific resource , 2015, Acta neurologica Scandinavica.
[26] Jan de Leeuw,et al. Gifi Methods for Optimal Scaling in R: The Package homals , 2009 .
[27] D. Wingerchuk,et al. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. , 2014, Mayo Clinic proceedings.
[28] D. Jensen. [Interferon therapy of multiple sclerosis]. , 1999, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.
[29] J. Lechner-Scott,et al. Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis , 2015, Annals of neurology.
[30] M. Sormani. Prognostic factors versus markers of response to treatment versus surrogate endpoints: Three different concepts , 2017, Multiple sclerosis.
[31] M. Tsolaki,et al. Data quality evaluation for observational multiple sclerosis registries , 2017, Multiple sclerosis.
[32] B. Weinshenker,et al. Multiple sclerosis. , 2000, The New England journal of medicine.
[33] G. Antonelli,et al. Predicting beta-interferon failure in relapsing-remitting multiple sclerosis , 2007, Multiple sclerosis.
[34] X. Montalban,et al. Roles of the ubiquitin peptidase USP18 in multiple sclerosis and the response to interferon‐β treatment , 2013, European journal of neurology.
[35] A. Terzic,et al. Big Data Transforms Discovery–Utilization Therapeutics Continuum , 2016, Clinical pharmacology and therapeutics.
[36] H. Butzkueven,et al. Observational data: Understanding the real MS world , 2016, Multiple sclerosis.
[37] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[38] À. Rovira,et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. , 2015, Brain : a journal of neurology.
[39] Jeffrey A. Cohen,et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.
[40] Gavin Giovannoni,et al. Serum neurofilament is associated with progression of brain atrophy and disability in early MS , 2017, Neurology.
[41] D. Karussis,et al. Sex-specific prediction of interferon beta therapy response in relapsing-remitting multiple sclerosis , 2015, Journal of Clinical Neuroscience.
[42] B. Casanova,et al. Response to interferon in multiple sclerosis is related to lipid-specific oligoclonal IgM bands , 2010, Multiple sclerosis.
[43] G. Le Teuff,et al. Clinical Parameters to Predict Response to Interferon in Relapsing Multiple Sclerosis , 2008, Neuroepidemiology.
[44] Robert Zivadinov,et al. MRI correlates of disability progression in patients with CIS over 48 months , 2014, NeuroImage: Clinical.
[45] X. Montalban,et al. Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients , 2016, Neurology: Neuroimmunology & Neuroinflammation.
[46] L. Kappos,et al. MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis , 2006, Multiple sclerosis.